GC240 MASLD And Alcoholic Liver Disease
MASLD (metabolic dysfunction-associated steatotic liver disease) and alcoholic liver disease are chronic hepatic conditions characterized by hepatic steatosis driven by metabolic dysfunction or excessive alcohol consumption, respectively, which can progress through steatohepatitis to fibrosis, cirrhosis, and hepatocellular carcinoma.
MASLD and Alcoholic Liver Disease
This GC 240 lecture by Prof. Wai-Kay Seto covers the entire spectrum of Steatotic Liver Disease (SLD), encompassing both Alcoholic Liver Disease (ALD) and Metabolic-Associated Steatotic Liver Disease (MASLD). It is a clinically high-yield lecture that bridges hepatology, endocrinology (metabolic syndrome), psychiatry (alcohol dependence/withdrawal), and surgery (liver transplantation). The lecture is structured around two case presentations that illustrate the two major arms of fatty liver disease.
Learning objectives (derived from slide outline) [1]:
- Understand the updated categorization of Steatotic Liver Disease (EASL 2024 nomenclature)
- Recognize, investigate, and manage Alcoholic Liver Disease – from steatosis through hepatitis to cirrhosis
- Understand MASLD epidemiology, risk stratification (FIB-4, elastography), and management (non-pharmacological and pharmacological)
- Appreciate multiorgan involvement of alcohol and the overlap between ALD and MASLD
Part 1: Steatotic Liver Disease — The Big Picture
The 2024 EASL classification replaces NAFLD/NASH with MASLD/MASH and unifies all fatty liver under the umbrella term "Steatotic Liver Disease (SLD)." [1]
High Yield – New Nomenclature
The old term NAFLD required exclusion of alcohol; the new term MASLD is an inclusion-based diagnosis requiring ≥1 cardiometabolic risk factor. This is a fundamental conceptual shift. "MetALD" now describes patients who have both metabolic risk factors AND significant alcohol intake.
| Old Term | New Term (EASL 2024) | Key Criteria |
|---|---|---|
| NAFLD | MASLD | Steatosis + ≥1 cardiometabolic risk factor |
| NASH | MASH | MASLD + inflammation + ballooning on biopsy |
| Alcoholic Fatty Liver Disease | ALD (under SLD) | Steatosis + significant alcohol intake |
| Overlap | MetALD | Both metabolic RF + alcohol |
| — | Other causes of SLD | Drugs, genetic, endocrine |
EASL 2024 alcohol thresholds for SLD classification [1]:
| Category | Women | Men |
|---|---|---|
| MASLD | Alcohol ≤ 20 g/day + ≥1 cardiometabolic RF | Alcohol ≤ 30 g/day + ≥1 cardiometabolic RF |
| MetALD | 20–50 g/day | 30–60 g/day |
| ALD | > 50 g/day | > 60 g/day |
What the EASL 2024 flowchart shows: steatosis on imaging/biopsy → cardiometabolic criteria → alcohol thresholds that split MASLD / MetALD / ALD — name the disease by alcohol grams + metabolic risk, not “fatty liver” alone. [1]
Cardiometabolic parameters that define MASLD [1]:
| Parameter | Threshold |
|---|---|
| BMI | ≥ 25 kg/m² (≥ 23 kg/m² for Asians) |
| Waist circumference | ≥ 94 cm ♂ / ≥ 80 cm ♀ (Europeans); ≥ 90 cm ♂ / ≥ 80 cm ♀ (South Asians & Chinese) |
| Prediabetes | HbA1c 5.7–6.4%, or FPG 5.6–6.9 mmol/L, or 2-h OGTT 7.8–11 mmol/L |
| Type 2 Diabetes | HbA1c ≥ 6.5%, or FPG ≥ 7.0 mmol/L, or 2-h OGTT ≥ 11.1 mmol/L, or on T2DM treatment |
| Hypertriglyceridemia | ≥ 1.7 mmol/L (≥ 150 mg/dL), or on lipid-lowering treatment |
| Low HDL | ≤ 1.0 mmol/L ♂ / ≤ 1.3 mmol/L ♀, or on lipid-lowering treatment |
| Hypertension | ≥ 130/85 mmHg, or on antihypertensive treatment |
| Modality | What It Shows | Thresholds |
|---|---|---|
| Ultrasound | Bright/hyperechoic liver, deep attenuation, vascular blunting | Qualitative; operator-dependent |
| Liver elastography (CAP score) | Controlled Attenuation Parameter measures steatosis | Steatosis ≥ 248 dB/m; Severe steatosis ≥ 280 dB/m |
| MRI (specific sequence — MRI-PDFF) | Proton density fat fraction; most accurate non-invasive | Research/specialist setting |
| Liver biopsy | Gold standard; shows inflammation, ballooning, fibrosis | Steatosis > 5% of hepatocytes |
Assessment requires: (1) Detailed drinking history, (2) Cardiometabolic risk factors, (3) Drug history (corticosteroids / tamoxifen / valproate / methotrexate), (4) Concomitant liver disease, (5) Other causes (hypothyroid / PCOS / panhypopituitarism / bypass surgery / genetic), (6) LFTs (ALT/AST), (7) Platelet count. [1]
Why platelet count? Because thrombocytopenia is a surrogate marker for portal hypertension and advanced fibrosis (hypersplenism from portal HTN → splenic sequestration). It also feeds into the FIB-4 calculation.
Part 2: Alcohol and the Liver
The lecture opens with a 58-year-old male lab worker found jaundiced, drinking 1 bottle of whisky/day for 10+ years.
Key observations from his bloodwork:
- Bilirubin 145 μmol/L → significant hepatocellular dysfunction
- AST 278, ALT 191 → AST > ALT (ratio ~1.5:1) — classic for alcoholic hepatitis [1]
- GGT 1155 U/L → massively elevated; alcohol is the most potent inducer of GGT
- INR 1.9 → impaired synthetic function / coagulopathy
- Amylase 214 → mildly elevated; possible concomitant pancreatitis
- Splenomegaly on USG → portal hypertension / cirrhosis
His course: psychiatry input for alcohol abstinence, lorazepam for withdrawal, IV thiamine, nutritional support → LFTs improved by day 5. On day 6, haematemesis from esophageal variceal bleeding requiring banding → cirrhotic complication unmasked.
What the OGD images show: blood-filled oesophagus then a banded varix — ALD is not “just LFT numbers”; portal hypertension declares itself mid-admission. [1]
One Alcoholic Unit = One Standard Drink = 10 g Ethanol
| Drink | Volume for 1 Unit |
|---|---|
| Beer (5%) | 250 mL |
| Red wine (12%) | 100 mL |
| Spirits (40%) | 30 mL |
| Soju (16-20%) | ~60-65 mL |
| Sake (15-22%) | ~45-65 mL |
| Baijiu (40-58%) | ~17-25 mL |
Common serving sizes and their alcohol units (HK Department of Health conversion chart) [1]:
| Serving | Beverage | Units |
|---|---|---|
| 1 glass (180 mL) | Beer / alcopops | 0.7 |
| 1 can (330 mL) | Beer / alcopops | 1.3 |
| 1 can (500 mL) | Beer / alcopops | 2.0 |
| 1 bottle (640 mL) | Beer / alcopops | 2.5 |
| 1 glass (125 mL) | Red / white wine / champagne | 1.2 |
| 1 peg (40–50 mL) | Spirits | 1.3 |
| 1 shot (22 mL) | Spirits | 0.7 |
| 1 glass (180 mL) | Rice wine | 5.7 |
| 1 maotai glass | Maotai | 0.8 |
| 1 small cup (20 mL) | Japanese sake | 0.3 |
10 g ethanol = 12.6 mL pure alcohol [1]
Exam Trap – Calculating Alcohol Intake
If a stem says "1 bottle of whisky (700 mL, 40%) per day," that is approximately 700 × 0.40 × 0.789 (density) ≈ 221 g of ethanol/day = ~22 standard drinks. Far above the dangerous threshold. Always convert to grams.
Safety level (controversial): Men 20-30 g/day; Women 10-20 g/day. Binge drinking is harmful regardless of average intake.
If drinking 50-60 g/day [1]:
| Condition | Time to Develop |
|---|---|
| Alcoholic steatosis | 2+ years |
| Alcoholic hepatitis | 5+ years |
| Alcoholic liver cirrhosis | 5-20 years |
Why are these only gross estimations? Drinking histories are notoriously unreliable. Concomitant liver disease (viral hepatitis, metabolic syndrome) accelerates progression dramatically [1].
Global burden: Alcohol accounts for 25% of global cirrhosis and 19% of global HCC [1].
The lecture references the AUDIT (Alcohol Use Disorders Identification Test) endorsed by the HK Department of Health. This is a 10-question screening tool assessing hazardous/harmful drinking and dependence [1].
Structure: The first 3 questions form the AUDIT-C (screening subset covering frequency, quantity, and binge episodes). If AUDIT-C score ≥ 3, the remaining 7 questions are completed.
AUDIT score interpretation [1]:
| Total Score | Category | Action |
|---|---|---|
| 0 | Non-drinker | Encourage continued abstinence |
| 1–7 | Lower-risk drinking | Advise to drink less; limit to 2 units/day (men) or 1 unit/day (women) |
| 8–15 | Increasing risk | Brief intervention; advise to cut down |
| 16–19 | Harmful drinking | Professional support before attempting reduction |
| ≥ 20 | Probable dependence | Specialist referral for evaluation and treatment |
AUDIT-C Q3 score ≥ 1 indicates binge drinking (≥ 5 drinks in a row) [1].
GGT can be > 1,000 U/L but is not specific. AST > ALT during hepatitis (AST usually < 400 U/L). Serum ethanol has a half-life of 4-5 hours. Phosphatidylethanol (PEth) is the most sensitive and specific biomarker.
| Biomarker | Sensitivity/Specificity | Detection Window | Key Points |
|---|---|---|---|
| GGT | Low specificity | Days-weeks | Induced by alcohol, drugs, obesity |
| AST:ALT ratio | Moderate | At time of testing | ≥ 1.5:1 in alcoholic hepatitis; AST seldom > 400 U/L |
| Serum ethanol | High (if timed) | 4-5 hour half-life | Only useful acutely |
| PEth (Phosphatidylethanol) | Highly sensitive and specific | 3-5 weeks | > 20 μg/L = detectable with modest drinking; > 200 μg/L = heavy drinking |
| MCV (macrocytosis) | Low specificity | Weeks-months | Alcohol-related bone marrow toxicity |
Why is AST > ALT in alcoholic liver disease? Two reasons: (1) Alcohol causes mitochondrial damage (macromitochondria), and AST is predominantly mitochondrial; (2) Alcohol depletes hepatic pyridoxal 5'-phosphate (vitamin B6), which is a cofactor for ALT synthesis, so ALT production is relatively suppressed [2][3].
Alcohol causes multiple simultaneous presentations across organ systems.
| System | Manifestations |
|---|---|
| Liver | Steatosis, hepatitis, cirrhosis, HCC |
| Pancreas | Acute pancreatitis, chronic pancreatitis |
| CNS | Wernicke's encephalopathy, Korsakoff's syndrome, cerebellar degeneration, Marchiafava–Bignami disease, seizures |
| Psychiatric | Depression, anxiety, delirium tremens |
| Cardiovascular | Alcoholic cardiomyopathy, AF |
| Respiratory | ARDS, aspiration pneumonia |
| Musculoskeletal | Gout, myopathy, osteonecrosis, osteoporosis |
| Endocrine/Reproductive | Hypogonadism, fetal alcohol syndrome |
| Haematological | Macrocytosis, folate deficiency, thrombocytopenia |
| GI | Gastritis, Mallory-Weiss tears, GERD, oropharyngeal / esophageal / gastric / colorectal cancer |
| Renal/Metabolic | Urinary stones, gout |
Alcoholic liver disease: concomitant presentations to watch for [1]:
- Other organ involvement (psychiatric / CNS / cardiac / pancreatic)
- Poor nutritional status
- Alcoholic withdrawal (D2+ onward) — delirium tremens
- Infections
- Cirrhotic complications — variceal bleeding / ascites / SBP / HE
Alcoholic hepatitis: prolonged heavy drinking ( > 50-60 g/day). AST:ALT ratio ≥ 1.5:1 (AST seldom > 400 U/L). May have hepatic decompensation (↑INR, Bilirubin). ± abdominal discomfort / jaundice / low-grade fever. ± hemolysis (Zieve's syndrome).
Zieve's syndrome: A triad of alcoholic hepatitis + hyperlipidemia + hemolytic anemia. The hemolysis is thought to be caused by altered lipid composition of RBC membranes.
Must exclude [1]:
- Biliary obstruction (imaging)
- Other types of hepatitis (viral, autoimmune, drug-induced)
Critical Exam Point
Anyone presenting with chronic liver disease and a history of alcoholism — you MUST exclude other causes. Viral hepatitis (HBV, HCV), autoimmune hepatitis, and MASLD are all common concomitant conditions. Do NOT get tunnel-visioned by alcohol alone [4].
| Score | Components | Severe Threshold |
|---|---|---|
| Maddrey's Discriminant Function (mDF) | 4.6 × (patient PT – control PT) + Bilirubin (mg/dL) | ≥ 32 = Severe |
| MELD Score | INR / Bilirubin / Creatinine (logarithmic formula) | ≥ 21 = Severe |
Why do these matter? Patients crossing these thresholds have high short-term mortality (~35-50% at 28 days without treatment) and are candidates for specific pharmacological intervention [1][5].
The cornerstone is ALCOHOL ABSTINENCE (check compliance!) and SUPPORTIVE CARE.
Supportive measures (very important) [1]:
-
Nutritional support:
- Thiamine (IV) — prevents/treats Wernicke's encephalopathy. Must be given BEFORE glucose to avoid precipitating Wernicke's.
- Folate, phosphate, magnesium replacement
- Caloric support: Protein intake 1.2-1.5 g/kg/day — contrary to the old dogma of protein restriction (which is now discouraged except in severe HE)
- Correct electrolytes
-
Assess infection risk — workup and treat aggressively
-
Manage liver-related complications if present:
- Variceal bleeding → endoscopic banding
- Ascites → diuretics, paracentesis
- SBP → antibiotics
- Hepatic encephalopathy → lactulose, rifaximin
-
Assess and manage other acute alcohol-related conditions:
- Encephalopathy / Delirium tremens (typically D2+ after cessation) / Psychiatric
- Pancreatitis
-
Assess for acute kidney injury
-
Assess need for ICU support (may be difficult — these patients can deteriorate rapidly)
For mDF ≥ 32 or MELD ≥ 21:
| Treatment | Mechanism | Key Points |
|---|---|---|
| N-acetylcysteine (NAC) IV infusion | Antioxidant; replenishes glutathione | Only modest effect; used as adjunct |
| Prednisolone 40 mg daily | Anti-inflammatory; reduces hepatic inflammation | Improved mortality. Difficult decision due to risk of infection / GI bleeding. Stop if no treatment response by Day 4 (Lille score). If response → gradual taper |
| Liver transplantation | Definitive for end-stage | See below |
Why is glucocorticoid use a "difficult decision"? Alcoholic hepatitis patients are already immunocompromised (liver failure impairs opsonization, complement, and reticuloendothelial function). Adding steroids further increases infection risk. Active infection and GI bleeding are relative contraindications [1][6].
Lille score: Assessed at day 7 of steroid therapy. A Lille score > 0.45 indicates non-response → stop steroids (no benefit, only harm from continued immunosuppression).
Deceased Donor: Contraindicated in HK if last drink < 6 months. Living Donor: Can be considered if last drink ≥ 6 months; individualized. Need comprehensive psychosocial assessment. Issue of alcoholic relapse. Need to demonstrate commitment to abstinence.
| Parameter | Hong Kong Rule |
|---|---|
| Deceased donor | Contraindicated if last drink < 6 months |
| Living donor | Can be considered if last drink ≥ 6 months; individualized |
| Psychosocial assessment | Mandatory |
| Key concern | Alcoholic relapse post-transplant (10-30%) [7] |
HK-Specific Exam Point
The 6-month abstinence rule is the standard in Hong Kong for deceased donor liver transplantation. This is a commonly tested threshold. In other regions, early transplantation for severe alcoholic hepatitis (without 6-month rule) is increasingly accepted but remains controversial [1].
Part 3: Metabolic-Associated Steatotic Liver Disease (MASLD)
A 74-year-old female, BMI 28.6, with poorly controlled T2DM (HbA1c 9.1%), CKD (eGFR 30), hypertension, dyslipidemia, minor CAD. Found to have a 4.8 cm HCC on CT — despite being HBsAg−, Anti-HCV−, Anti-HBc−. The liver had a lobular surface suggesting cirrhosis.
Teaching point: This patient developed HCC from MASLD/MASH-related cirrhosis without any viral hepatitis. She died 7 months after diagnosis. This case powerfully illustrates that MASLD is now a significant cause of HCC even without viral hepatitis [1].
30-35% prevalence in Asia. Main risk factors: Obesity/overweight (65%), T2DM (65-70%). 20% progress to MASH. Advanced fibrosis (F3): ~5-8%. Cirrhosis: ~3%. As sole liver disease: 11% of cirrhosis, 12% of HCC (much higher when concomitant with other liver diseases).
| Parameter | Value |
|---|---|
| Prevalence in Asia | 30-35% |
| Obesity/overweight association | 65% |
| T2DM association | 65-70% |
| Progression to MASH | ~20% |
| Advanced fibrosis (F3) | ~5-8% |
| Cirrhosis | ~3% |
| Sole cause of cirrhosis | 11% |
| Sole cause of HCC | 12% |
Why is this important? With rising obesity and diabetes in Asia (China's obesity prevalence went from 3.1% in 2004 to 8.1% in 2018; 52% of Chinese diabetics are untreated), MASLD is becoming one of the fastest-growing causes of liver disease and HCC [1].
| Feature | Steatosis (MASLD) | Steatohepatitis (MASH) |
|---|---|---|
| Histology | Fat in liver only | Inflammation + ballooning |
| Risk of progression | Low | Increased risk of fibrosis, cirrhosis, HCC |
| ALT/AST | May be normal or mildly elevated | Elevated (but low accuracy for diagnosis) |
| Non-invasive biomarker | Imaging (USG, elastography) | No good non-invasive biomarker |
| Natural history | Can progress to MASH; dynamic changes with time | Can "burn out" in late-stage (steatosis disappears as cirrhosis develops) |
"Burn-out" concept: In advanced MASLD cirrhosis, the fat disappears from the liver because the hepatocytes are replaced by fibrotic tissue. This makes it hard to diagnose MASLD retrospectively in a cirrhotic liver — hence the term "cryptogenic cirrhosis" may actually be burned-out MASLD [1].
Fibrosis progression risk factors [1]:
- Diabetes mellitus
- Insulin resistance
- Elevated liver enzymes
- Weight gain
Key: Exclude Advanced Fibrosis using FIB-4. Then confirm with elastography if needed.
FIB-4 is the most important test in MASLD. It should be part of T2DM complication screening.
FIB-4 Formula: Age × AST / (Platelet count × √ALT)
⚠️ Use FIB-4 with caution in patients < 35 or > 65 years old — the score is less reliable at these age extremes [1].
| FIB-4 Score | Interpretation | Action |
|---|---|---|
| < 1.3 | Low risk of advanced fibrosis | Reassess in 1-3 years |
| 1.3 – 2.67 | Indeterminate | Proceed to VCTE (Vibration Controlled Transient Elastography) |
| > 2.67 | High risk of advanced fibrosis | Specialist referral |
Why FIB-4? It uses routinely available blood tests (age, AST, ALT, platelets) — no additional cost. It has excellent negative predictive value for excluding advanced fibrosis [1].
Who should be screened with FIB-4? (EASL 2024) [1]:
- Patients with type 2 diabetes
- Patients with obesity + ≥ 1 cardiometabolic risk factor
- Patients with persistently elevated liver enzymes
FIB-4 should be part of T2DM complication screening [1].
VCTE thresholds (from EASL 2024 pathway shown in slides) [1]:
- VCTE ≥ 8 kPa → suspected significant fibrosis → consider pharmacotherapy
- VCTE ≥ 12 kPa → suggestive of cirrhosis [8]
Must assess both liver AND non-liver complications.
Cardiometabolic:
- T2DM / prediabetes (HbA1c, FBG)
- Obesity assessment
- Dyslipidemia
- Cardiovascular risk assessment
Other:
- OSA (obstructive sleep apnea) — strongly associated with MASLD
- Kidney disease — CKD is common in metabolic syndrome
- HCC surveillance for advanced fibrosis and cirrhosis: USG ± AFP
- Liver biopsy (occasionally, for diagnostic uncertainty)
- MRI-PDFF (research/specialist)
Part 4: Management of MASLD
Weight loss is the cornerstone treatment.
| Target Condition | Weight Loss Required |
|---|---|
| Simple steatosis | 5% |
| Inflammation (↑ALT) | 7% |
| Fibrosis | 10% |
| Normal body weight | 3-5% |
Dietary strategies [1]:
- Hypocaloric diet ( < 1,000 kcal/day)
- Ketogenic diet (Carb: < 20-50 g/day)
- Time-restricted eating (uncertain evidence)
- Mediterranean diet pattern (high in olive oil, fish, vegetables; base of whole grains, legumes, nuts, seeds, herbs/spices; moderate fish ≥ 2×/week; limited red meat and sweets) [1]
- ↓ Ultra-processed foods (red meat)
- ↓↓ Sugar-sweetened beverages (fructose) — fructose is directly lipogenic in the liver via de novo lipogenesis
- Coffee!! (≥ 3 cups per day) — protective against fibrosis progression
Exercise [1]:
- > 150 min/week moderate intensity OR > 75 min/week high intensity
- Reduce sedentary time
Other: Reduce smoking and alcohol [1]
Coffee — A Genuine Hepatoprotective Agent
This is not a joke. Multiple large meta-analyses show that ≥3 cups of coffee per day reduces risk of fibrosis progression, cirrhosis, and HCC. The mechanism involves anti-inflammatory and antioxidant properties of coffee polyphenols. Prof. Seto specifically highlights this on slides [1].
Pharmacological Treatment [1]
Resmetirom is a liver-directed thyroid hormone receptor (THR-β) agonist. Indicated for suspected MASH with fibrosis (VCTE ≥ 8 kPa). NOT licensed for cirrhosis. NOT available in Asia. Modest effect: 25-30% with MASH resolution and fibrosis improvement.
Why a thyroid receptor agonist? THR-β activation in hepatocytes increases mitochondrial fatty acid oxidation, reduces hepatic fat, and lowers atherogenic lipoproteins. It is liver-selective (avoids cardiac/bone effects of systemic thyroid hormones).
Semaglutide — GLP-1 receptor agonist. Body weight/fat loss via: suppressing glucagon, activating insulin, ↓gastric emptying, ↓appetite. 36-62% MASH treatment response. Mean weight loss > 10%. Need gradual dose escalation. Oral version available in future. Indication: suspected MASH with fibrosis (VCTE ≥ 8 kPa).
Multi-system effects of GLP-1 receptor agonists [1]:
| System | Beneficial Effects |
|---|---|
| Brain | ↑ Satiety, ↑ memory & motor function, ↓ neuroinflammation |
| Cardiovascular | ↑ CV protection, ↑ anti-inflammatory action, ↓ myocardial ischemic injury, ↓ endothelial dysfunction, ↓ triglyceride/VLDL, ↑ HDL, ↑ ANP secretion |
| Liver | ↑ Hepatic insulin sensitivity, ↓ de novo lipogenesis/liver fat, ↓ hepatic steatosis, ↓ hepatic glucose production, ↓ oxidative & ER stress, ↓ liver enzymes |
| Pancreas | ↑ Insulin synthesis & secretion (β-cells), ↓ glucagon secretion (α-cells), ↑ β-cell protection & proliferation |
| Kidney | ↓ Decline in eGFR, ↓ new-onset macroalbuminuria, ↓ renal tubular Na⁺ reabsorption |
| Adipose tissue | ↓ Adipose insulin resistance, ↓ lipolysis, ↓ TNF-α/IL-6/leptin, ↑ adiponectin |
| GI tract | ↓ Gastric emptying, ↓ GI peristalsis |
GLP-1A side effects [1]:
| Side Effect | Notes |
|---|---|
| GI | Gastroparesis, vomiting, nausea (most common; dose-dependent) |
| GI (other) | Constipation, abdominal pain |
| Pancreatitis | Mainly older versions (exenatide); rare with semaglutide |
| Gallstones | Reduced gallbladder motility from weight loss |
| Cosmetic | "Ozempic Face" — facial fat loss/volume loss with rapid weight reduction |
Off-Label Use Warning
GLP-1 agonists are increasingly used off-label for weight loss alone. The lecture specifically notes this. Be aware that in exam settings, the indication for GLP-1A in MASLD is specifically suspected MASH with fibrosis (VCTE ≥ 8 kPa), not simple steatosis [1].
| Agent | Status |
|---|---|
| Vitamin E | Uncertain; possible increased all-cause mortality |
| Statins | Safe to use in MASLD (do not withhold for fear of liver damage) |
| Metformin | Safe to use but no direct anti-fibrotic effect |
| SGLT2 inhibitors | Safe to use |
| Bariatric endoscopy/surgery | Effective for morbidly obese patients |
| Pioglitazone | Insulin sensitizer; high MASH resolution (~46–50%) and fibrosis improvement (~40–44%); limited by weight gain and heart failure risk [10] |
| Agent | Class | Approximate Efficacy (from comparative data) [1] |
|---|---|---|
| Tirzepatide | Dual GIP/GLP-1 agonist | Among highest MASH resolution & fibrosis improvement |
| Efruxifermin | FGF21 analogue | ~74% MASH resolution, ~41% fibrosis improvement |
| Pegozafermin | FGF21 analogue | High efficacy (data emerging) |
| Semaglutide (high dose) | GLP-1 agonist | ~60% MASH resolution, ~44% fibrosis improvement |
| Lanifibranor | Pan-PPAR agonist | ~44% MASH resolution, ~43% fibrosis improvement |
| Resmetirom | THR-β agonist | ~28–32% MASH resolution, ~25–28% fibrosis improvement |
| Oral GLP-1A | Next-generation oral formulations | Data emerging |
Treating co-morbidities is also important! The #1 cause of death in MASLD patients is cardiovascular disease, not liver disease. Managing hypertension, dyslipidemia, and diabetes aggressively is essential.
Part 5: Alcohol Metabolism & Pathogenesis (Integrated from Supporting Sources)
Understanding the pathophysiology helps you answer "why" questions in exams.
-
Alcohol Dehydrogenase (ADH) pathway (80%):
- Ethanol → Acetaldehyde (+ NADH) → Acetate/Acetyl-CoA (via ALDH, also + NADH)
- Excess NADH shifts redox state: impairs gluconeogenesis (→ hypoglycemia), impairs Krebs cycle (→ ketoacidosis), promotes fatty acid synthesis
- Acetaldehyde forms protein adducts → immune activation → hepatocyte injury
-
Microsomal Ethanol-Oxidizing System (MEOS) (20%):
- CYP2E1 oxidizes ethanol → acetate + reactive oxygen species (ROS)
- ROS → lipid peroxidation → mitochondrial damage
- CYP2E1 also metabolizes paracetamol → chronic alcoholics are more susceptible to paracetamol hepatotoxicity
-
Gut permeability: Alcohol increases intestinal permeability → endotoxin (LPS) enters portal circulation → Kupffer cell activation → TNF-α, IL-6 release → hepatic inflammation and fibrosis
| Stage | Histological Features |
|---|---|
| Alcoholic fatty liver | Macrovesicular/microvesicular steatosis, perivenular distribution |
| Alcoholic hepatitis | Spotty necrosis, ballooning degeneration, neutrophil infiltration, perivenular/perisinusoidal/pericellular fibrosis, Mallory-Denk bodies |
| Alcoholic cirrhosis | Bridging fibrosis, regenerative nodules, distorted architecture |
Mallory-Denk bodies: Eosinophilic intracytoplasmic inclusions of damaged cytokeratin intermediate filaments. Not specific to alcohol (also seen in MASH, Wilson's, HCC) but suggestive of alcohol-induced injury [7].
From the cirrhosis and CFB examination slides [11][12]:
| Region | ALD-Specific Signs |
|---|---|
| Hands | Dupuytren's contracture, palmar erythema, leukonychia, asterixis |
| Face | Jaundice, parotid gland swelling (fatty infiltration), fetor hepaticus |
| Chest | Spider naevi, gynecomastia, loss of chest/axillary hair |
| Abdomen | Hepatomegaly (may be present even with cirrhosis in ALD), splenomegaly, ascites, caput medusae |
| Genitalia | Testicular atrophy (direct gonadal toxicity + increased estrogen:androgen ratio) |
| Legs | Edema, muscle wasting, bruising |
Exam Intelligence
| Trap | Correct Understanding |
|---|---|
| "ALT > AST in all liver disease" | In ALD (especially alcoholic hepatitis), AST > ALT (ratio ≥ 1.5-2:1). Also reversed in cirrhosis of any cause and HCC. [1][2] |
| "AST > 500 in alcoholic hepatitis" | AST seldom > 400 U/L in alcoholic hepatitis. If > 500-1000, think drug-induced (paracetamol), viral, or ischemic hepatitis [1] |
| "NAFLD = no alcohol" | MASLD (new term) uses inclusion criteria (cardiometabolic RF), not exclusion of alcohol. MetALD covers the overlap. [1] |
| "Prednisolone for all alcoholic hepatitis" | Only for SEVERE (mDF ≥ 32 or MELD ≥ 21). Stop if no response by D4-7. Contraindicated with active infection/GI bleeding. [1] |
| "Weight loss of 5% is enough for fibrosis" | 5% for steatosis, 7% for inflammation, 10% for fibrosis. [1] |
| "Statins are contraindicated in fatty liver" | Statins are SAFE in MASLD. [1] |
| "FIB-4 is a fibrosis-specific test" | FIB-4 is a screening/exclusion tool with high NPV. It does NOT confirm fibrosis; indeterminate results need elastography [1] |
| "Liver transplant immediately for ALD" | 6-month abstinence rule in HK (deceased donor). Living donor can be individualized. [1] |
| "HCC screening for all MASLD" | Only for advanced fibrosis/cirrhosis in MASLD. In HBV, earlier due to direct carcinogenesis. [8][9] |
| Pattern | AST:ALT | GGT | Other Clues | Diagnosis |
|---|---|---|---|---|
| AST > ALT (ratio ≥ 2:1), AST < 400 | Reversed | Markedly elevated ( > 1000) | MCV elevated, drinking history | Alcoholic hepatitis |
| ALT > AST, both mildly elevated | Normal ratio | Mildly elevated | BMI elevated, metabolic RF | MASLD |
| AST > ALT, both markedly elevated ( > 1000) | Reversed | Variable | Shock history, rapid decline | Ischaemic hepatitis |
| ALT > AST, markedly elevated ( > 1000) | Normal ratio | Variable | Viral markers positive | Acute viral hepatitis |
| AST > ALT in chronic disease | Reversed | Variable | Cirrhotic stigmata | Cirrhosis of any cause |
| Related Lecture | Connection |
|---|---|
| GC 026: Cirrhosis & Ascites | Management of cirrhotic complications (varices, ascites, SBP, HRS) that complicate ALD/MASLD [18] |
| GC 025: Liver Failure | Acute-on-chronic liver failure, MELD scoring, hepatic encephalopathy [6] |
| GC 161: Alcohol & the Brain | Wernicke-Korsakoff, delirium tremens, psychiatric comorbidities |
| GC 064: I am Overweight | Obesity management, metabolic syndrome overlap with MASLD |
| LFT Data Interpretation | AST:ALT patterns, isolated GGT elevation, FIB-4 calculation [2] |
| GI Interactive Tutorial | Case 2: Dual liver disease (HBV + MASLD), FIB-4, elastography, HCC surveillance [8] |
High Yield Summary
-
Steatotic Liver Disease (SLD)
- is the umbrella term (EASL 2024) covering MASLD, ALD, MetALD, and other causes.
-
Alcoholic Liver Disease
- One standard drink = 10g ethanol.
- AST:ALT ≥ 1.5:1 (AST < 400 U/L).
- PEth is the best biomarker (3-5 week window).
- Severe alcoholic hepatitis (mDF ≥ 32 or MELD ≥ 21) → Prednisolone 40mg daily (stop if no response by D4-7) + NAC.
- Always give IV thiamine + nutritional support.
- Watch for withdrawal (D2+), infections, variceal bleeding, and multiorgan alcohol damage.
- Liver transplant requires 6-month abstinence in HK (deceased donor).
-
MASLD
- 30-35% prevalence in Asia.
- FIB-4 is the most important screening test (part of T2DM complication screening).
- Weight loss targets: 5% for steatosis, 7% for inflammation, 10% for fibrosis.
- Coffee ≥ 3 cups/day is hepatoprotective.
- Resmetirom (THR-β agonist) and semaglutide (GLP-1A) are emerging therapies for MASH with fibrosis (VCTE ≥ 8 kPa).
- Statins, metformin, and SGLT2i are safe in MASLD.
- HCC surveillance only for advanced fibrosis/cirrhosis.
-
Critical exam discriminators
- AST seldom > 400 in alcoholic hepatitis (if > 400, think viral/ischemic/drug).
- MASLD uses inclusion criteria, not exclusion of alcohol.
- Alcoholic cirrhosis is NOT a contraindication to transplant (with abstinence).
- The #1 killer in MASLD is CVD, not liver disease.
Active Recall - MASLD and Alcoholic Liver Disease
[1] Lecture slides: GC 240. MASLD and Alcoholic Liver Disease.pdf (all pages) [2] Lecture slides: Gastroenterology Hepatology Introduction to GI:Hepatology investigations from the abnormal.pdf (p8) [3] Senior notes: Ryan Ho GI.pdf (pp305-307) [4] Senior notes: Block A - Gastrointestinal Data Interpretation.pdf (p5) [5] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf (p784) [6] Senior notes: Block A - A jaundiced and incoherent patient_ liver failure.pdf (p12) [7] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf (pp774-777) [8] Senior notes: Block A - Gastroenterology Interactive Tutorial.pdf (p2) [9] Lecture slides: GC 026. Abdominal distension_ascites and cirrhosis.pdf (p34) [10] Senior notes: Maksim Medicine Notes.pdf (p148) [11] Senior notes: MBBS Final MB (Surgery) (Felix PY Lai).pdf (pp480-483) [12] Lecture slides: CFB (MED07) Examination of the Abdomen.pdf [18] Lecture slides: GC 026. Abdominal distension_ascites and cirrhosis.pdf (pp2, 35)
GC239 Viral Hepatitis HAV: HBV: HCV: HEV
Viral hepatitis encompasses liver inflammation caused by hepatotropic viruses, including HAV (fecal-oral, acute, self-limited), HBV (bloodborne/sexual, can become chronic with risk of cirrhosis and hepatocellular carcinoma), HCV (bloodborne, frequently chronic leading to cirrhosis), and HEV (fecal-oral, usually self-limited but potentially fulminant in pregnancy).
GC241 A Short Course Of Dementia
A structured, condensed educational course designed to provide an overview of dementia, covering its types, pathophysiology, clinical features, diagnosis, and management principles for healthcare learners.